Zacks: Analysts Anticipate Insmed Incorporated (NASDAQ:INSM) Will Post Quarterly Sales of $58.83 Million

Wall Street brokerages expect that Insmed Incorporated (NASDAQ:INSMGet Rating) will post sales of $58.83 million for the current fiscal quarter, according to Zacks Investment Research. Six analysts have issued estimates for Insmed’s earnings, with estimates ranging from $55.76 million to $61.62 million. Insmed posted sales of $45.37 million in the same quarter last year, which would indicate a positive year over year growth rate of 29.7%. The company is expected to announce its next earnings results on Monday, January 1st.

On average, analysts expect that Insmed will report full-year sales of $251.28 million for the current financial year, with estimates ranging from $245.10 million to $258.67 million. For the next year, analysts anticipate that the company will report sales of $342.90 million, with estimates ranging from $324.10 million to $375.29 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Insmed.

Insmed (NASDAQ:INSMGet Rating) last announced its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($0.91) by $0.11. Insmed had a negative net margin of 217.35% and a negative return on equity of 108.20%. The company had revenue of $53.10 million during the quarter, compared to the consensus estimate of $53.36 million. During the same period last year, the firm earned ($0.89) earnings per share. Insmed’s revenue was up 32.1% compared to the same quarter last year.

A number of research analysts have weighed in on INSM shares. StockNews.com initiated coverage on shares of Insmed in a report on Thursday, March 31st. They issued a “hold” rating for the company. SVB Leerink dropped their target price on shares of Insmed from $57.00 to $52.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 22nd. The Goldman Sachs Group lowered their price target on shares of Insmed from $56.00 to $48.00 and set a “buy” rating on the stock in a research report on Tuesday, May 24th. Finally, Zacks Investment Research lowered shares of Insmed from a “buy” rating to a “hold” rating in a research report on Wednesday, May 11th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $46.67.

Shares of Insmed stock opened at $19.53 on Monday. The company has a debt-to-equity ratio of 6.73, a current ratio of 6.04 and a quick ratio of 5.52. The firm has a fifty day moving average price of $21.80 and a 200 day moving average price of $23.76. Insmed has a 1 year low of $16.41 and a 1 year high of $34.44. The stock has a market cap of $2.33 billion, a PE ratio of -5.17 and a beta of 2.07.

In other Insmed news, CEO William Lewis sold 96,614 shares of the firm’s stock in a transaction dated Wednesday, March 23rd. The shares were sold at an average price of $23.16, for a total transaction of $2,237,580.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Melvin Md Sharoky bought 20,000 shares of the company’s stock in a transaction on Wednesday, May 11th. The shares were acquired at an average price of $17.20 per share, with a total value of $344,000.00. Following the completion of the acquisition, the director now directly owns 262,621 shares in the company, valued at approximately $4,517,081.20. The disclosure for this purchase can be found here. 4.63% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Spire Wealth Management purchased a new stake in shares of Insmed during the fourth quarter valued at approximately $27,000. Point72 Hong Kong Ltd acquired a new position in Insmed in the fourth quarter worth $45,000. Advisor Group Holdings Inc. boosted its holdings in Insmed by 56.4% in the fourth quarter. Advisor Group Holdings Inc. now owns 2,140 shares of the biopharmaceutical company’s stock worth $58,000 after purchasing an additional 772 shares during the period. Lindbrook Capital LLC acquired a new position in Insmed in the fourth quarter worth $59,000. Finally, US Bancorp DE boosted its holdings in Insmed by 367.9% in the third quarter. US Bancorp DE now owns 2,569 shares of the biopharmaceutical company’s stock worth $70,000 after purchasing an additional 2,020 shares during the period.

Insmed Company Profile (Get Rating)

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Read More

Get a free copy of the Zacks research report on Insmed (INSM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.